Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

84.6%

-1.9% vs industry average

Late-Stage Pipeline

4%

1 trials in Phase 3/4

Results Transparency

0%

0 of 11 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
11(52.4%)
N/A
6(28.6%)
Phase 1
3(14.3%)
Phase 3
1(4.8%)
21Total
Phase 2(11)
N/A(6)
Phase 1(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT04354233Not ApplicableCompleted

A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer

Role: collaborator

NCT02813135Phase 1Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Role: collaborator

NCT05210413Phase 1Active Not Recruiting

Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

Role: collaborator

NCT02438761Phase 2Terminated

PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)

Role: collaborator

NCT02304809Phase 2Active Not Recruiting

Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations

Role: collaborator

NCT05427461Not ApplicableActive Not Recruiting

Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2

Role: collaborator

NCT03412058Not ApplicableActive Not Recruiting

Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

Role: collaborator

NCT04357873Phase 2Completed

Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations

Role: collaborator

NCT04263051Phase 2Completed

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Role: collaborator

NCT02299999Phase 2Active Not Recruiting

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Role: collaborator

NCT03951337Phase 2Active Not Recruiting

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

Role: collaborator

NCT02034981Phase 2Completed

Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1

Role: collaborator

NCT02117167Phase 2Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Role: collaborator

NCT03603847Completed

Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma

Role: collaborator

NCT03529383Not ApplicableCompleted

Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer

Role: collaborator

NCT02444390Not ApplicableCompleted

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Role: collaborator

NCT04007640Not ApplicableUnknown

Early Screening of Pancreatic Lesions : Development of New Imaging Tools

Role: collaborator

NCT02630368Phase 1Unknown

A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

Role: collaborator

NCT02505048Phase 2Completed

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

Role: collaborator

NCT01737450Phase 2Completed

Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive

Role: collaborator